Pancreatic Cancer Trial, Recruiting (NCT07536087)

Pancreatic Cancer Trial, Recruiting NCT07536087 Sponsor: Institute for Clinical and Experimental Medicine Condition: Pancreatic Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07536087 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pancreatic Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

A team of medical specialists has agreed that EUS-guided radiofrequency ablation (a procedure that uses heat to treat a lesion) is the right treatment for you (confirm with trial site)
You are able to understand and agree to take part in the study
You have a cyst in the pancreas (called a branch duct IPMN) that cannot be operated on, or you have chosen not to have surgery, AND the cyst has certain concerning features such as: yellowing of the skin, signs of high-grade abnormal cells or cancer, a solid lump larger than 5mm, or significant widening of the main pancreatic duct
You have a branch duct IPMN with certain risk features (such as a raised CA 19-9 blood marker, the cyst growing quickly, a cyst measuring 40mm or more, or new symptoms like diabetes or pancreatitis) — the number of risk features required depends on your overall health (confirm with trial site)
You have a specific type of pancreatic tumour called a neuroendocrine tumour (NET) that is smaller than 2cm
Your pancreatic neuroendocrine tumour has been confirmed through a tissue sample or, in some cases, through clinical assessment
A specific type of scan (68Ga-DOTATATE PET/CT) has shown the tumour is only in the pancreas and has not spread to lymph nodes, liver, or anywhere else in the body
Your tumour has been graded as low or intermediate (G1 or G2, with less than 5% cell activity on testing) (confirm with trial site)

Who may not be able to join:

You have a bleeding disorder that cannot be adequately controlled with medication
You are taking blood-thinning medication that cannot be safely stopped
You are unable to fully understand the purpose of the study or cooperate with the process, whether due to physical or psychological reasons
You are pregnant
You are unable to sign the consent form to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 420261363282

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07536087

Sponsor: Institute for Clinical and Experimental Medicine

Phase: Not Applicable

Status: Recruiting

Condition: Pancreatic Cancer

Trial contact: 420261363282

More information: https://clinicaltrials.gov/study/NCT07536087

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

A team of medical specialists has agreed that EUS-guided radiofrequency ablation (a procedure that uses heat to treat a lesion) is the right treatment for you (confirm with trial site)
You are able to understand and agree to take part in the study
You have a cyst in the pancreas (called a branch duct IPMN) that cannot be operated on, or you have chosen not to have surgery, AND the cyst has certain concerning features such as: yellowing of the skin, signs of high-grade abnormal cells or cancer, a solid lump larger than 5mm, or significant widening of the main pancreatic duct
You have a branch duct IPMN with certain risk features (such as a raised CA 19-9 blood marker, the cyst growing quickly, a cyst measuring 40mm or more, or new symptoms like diabetes or pancreatitis) — the number of risk features required depends on your overall health (confirm with trial site)
You have a specific type of pancreatic tumour called a neuroendocrine tumour (NET) that is smaller than 2cm
Your pancreatic neuroendocrine tumour has been confirmed through a tissue sample or, in some cases, through clinical assessment
A specific type of scan (68Ga-DOTATATE PET/CT) has shown the tumour is only in the pancreas and has not spread to lymph nodes, liver, or anywhere else in the body
Your tumour has been graded as low or intermediate (G1 or G2, with less than 5% cell activity on testing) (confirm with trial site)

Who may not be able to join:

You have a bleeding disorder that cannot be adequately controlled with medication
You are taking blood-thinning medication that cannot be safely stopped
You are unable to fully understand the purpose of the study or cooperate with the process, whether due to physical or psychological reasons
You are pregnant
You are unable to sign the consent form to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Institute for Clinical and Experimental Medicine

Registry

ClinicalTrials.gov

Start date

11 April 2026

Est. completion

31 December 2027

Where this trial is recruiting

🇨🇿 Czechia

Primary endpoints

Efficacy of EUS-RFA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov